Frances Balkwill - Queen Mary University of London
Frances Balkwill is Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, where she leads the Centre for Cancer and Inflammation. She is especially interested in translating knowledge of cancer biology into new biological treatments for cancer and has published 250+ scientific papers and reviews during her career. Much of her work focuses on the tumour microenvironment of ovarian cancer. In 2006, she was made a Fellow of the Academy of Medical Sciences and has served on its
Fran is also actively involved in communication of science to non-specialist audiences, especially young people. Fran is Director of the Centre of the Cell, a biomedical science centre for children, educational website and outreach project in East London. There have been more than 190,000 participants in Centre of the Cell activities since opening in September 2009. Fran's science communication work has been recognised by the award of the 2004 EMBO prize for communication in the Life Sciences and the 2005 Royal Society Michael Faraday Prize. In 2017, she was awarded the Cancer Research UK Inspiring Leadership in Research Engagement Prize.
Together with illustrator Mic Rolph, Fran has also produced thirteen science books for children on cell and molecular biology with titles such as Enjoy Your Cells, The Egg and Sperm Raceand You, Me and HIV. These books have been translated into at least twelve foreign languages with over half a million copies sold worldwide.
From 2009-2019 Fran was a non-parliamentary board member of the Parliamentary Office of Science and Technology, POST, and currently serves on CRUK and ERC grant committees. She is a Trustee of the charity Bloodwise. Fran was awarded an OBE in the 2008 Queen’s Birthday Honours list. In 2015 Fran was awarded the honorary degree of Doctor of Science honoris causa by the University of Bristol where she studied as an undergraduate.
Ernst Lengyel - Center for Integrative Science Chicago
Ernst Lengyel, MD, PhD, is an expert in the diagnosis and treatment of gynecologic malignancies, specifically, ovarian, cervical and endometrial cancers. His primary clinical focus is on the treatment of ovarian cancer, including advanced surgical techniques designed to improve patient outcomes.
Dr. Lengyel performed the University of Chicago's first laparoscopic pelvic and para-aortic lymph node dissection for gynecologic cancer. He also performs radical vaginal trachelectomy (RVT) to preserve fertility in young patients who have cervical cancer.
Dr. Lengyel has been recognized by Chicago magazine as one of the city's "Top Doctors" for ovarian and cervical cancer care. He is also skilled in complex pelvic surgeries for benign gynecologic conditions, such as endometriosis and fistula repairs.
Dr. Lengyel's research laboratory in the Center for Integrative Science focuses on the investigation of new therapies for the treatment of ovarian cancer. His research is funded by the National Institutes of Health (NIH). In addition to clinical and research activities, Dr. Lengyel mentors residents and postdoctoral fellows in the Department of Obstetrics/Gynecology.
Kunle Odunsi - Roswell Park Comprehensive Cancer Center Buffalo
Kunle Odunsi, MD, Ph.D., FRCOG, FACOG is the Cancer Center Deputy Director at Roswell Park Comprehensive Cancer Center. He is also The Robert, Anne & Lew Wallace Endowed Chair in Cancer Immunotherapy and Executive Director of the Center for Immunotherapy, the M. Steven Piver Endowed Professor and Chair of the Department of Gynecologic Oncology at Roswell Park. He provides operational oversight for the basic, translational and clinical research programs, as well as the educational missions of
Dr. Odunsi’s research interests focus on the mechanisms of immune recognition and tolerance in human ovarian cancer, and the translation of these understandings to human clinical trials. He has pioneered the pre-clinical and clinical development of antigen specific targeted vaccine therapies for the treatment of ovarian cancer, resulting in broad applicability to other solid tumors. His laboratory has identified important mechanisms of immune suppression within the ovarian cancer microenvironment; and he has developed strategies to counteract such. He is currently pioneering studies to “re-engineer” mature T cells and hematopoietic stem cells for generating sustained attack against ovarian cancer in patients. He has implemented multi-institutional immunotherapy clinical trials under the umbrella of the NCI Cancer Immunotherapy Trials Network (CITN); the NCTN (NRG); ETCTN; and the Cancer Vaccine Collaborative (CVC) program of the Cancer Research Institute/Ludwig Institute for Cancer Research. He has been awarded the Rosalind Franklin Prize for excellence in ovarian cancer research, and in 2018, was elected into the National Academy of Medicine, a distinguished lifetime designation that is considered one of the highest honors in health and medicine.
Dr. Odunsi has authored or co-authored more than 340 journal publications or book chapters including papers in the Proceedings of the National Academy of Sciences, USA, Nature Genetics, Immunity and New England Journal of Medicine. He is the Principal Investigator of an NCI-funded multi-million-dollar Specialized Program of Research Excellence (SPORE) in ovarian cancer. He is also Principal Investigator of a multi-million dollar grant from NYSTEM to pioneer a novel strategy of re-programing human hematopoietic stem cells to become a life-long supply of anti-tumor immune cells in patients.
Dr. Odunsi is Co-Chair of the of the NIH/NCI Cancer Moonshot Immuno-oncology Translational Network (IOTN); and was recently appointed Chairperson-elect of the AACR Cancer Immunology Working Group. He serves on several scientific advisory boards, including the NCI/NIH, Cancer Research Institute, Ovarian Cancer Research Fund, and the Marsha Rivkin Center for Ovarian Cancer Research. In addition, he serves on editorial boards of several prominent journals including Cancer Immunology Research, OncoImmunology, and Gynecologic Oncology.
Celeste Leigh Pearce, University of Michigan
Dr. Pearce earned her PhD at the University of Southern California and had extensive training in genetics at what is now the Broad Institute of MIT and Harvard. She is currently an Associate Professor in the Department of Epidemiology in the School of Public Health at the University of Michigan. She collaborates with investigators from all over the world and is a founding member of the Ovarian Cancer Association Consortium
Yvette Drew - University of British Columbia
Amit Oza -Princess Margaret Cancer Centre
Hans Nijman - Rijksuniversiteit Groningen in The Netherlands
Carolina Ilkow - Ottawa Hospital Research Institute
Carolina Ilkow, PhD. is originally from Buenos Aires, Argentina where she obtained her combined Bachelor’s and Master’s degree in Science. She then decided to move to Edmonton, Canada to continue her graduate studies at the University of Alberta, where she obtained her PhD in cell biology, after which she joined Dr. John Bell’s lab as a post-doctoral fellow. Carolina’s work in the Bell lab aimed at developing novel and tailored virotherapies to fight Pancreatic cancer. In July 2016, Carolina was recruited as
Joanne Kotsopoulos - Women’s College Research Institute Toronto
Dr. Joanne Kotsopoulos is a Scientist with the Familial Breast Cancer Research Unit at the Women’s College Research Institute, Women’s College Hospital and an Associate Professor at the University of Toronto. She received her PhD from the University of Toronto in 2007 and subsequently conducted her post-doctoral research training at the Channing Division of Network Medicine, Brigham and Women's Hospital.
Dr. Kotsopoulos directs a wide-range of research initiatives to further our understanding of BRCA-associated breast and ovarian cancer, with the goal of identifying viable strategies that confer substantial risk reduction and improve outcomes. Her studies have demonstrated an important role of hormonal, reproductive and modifiable exposures on BRCA-associated cancer development. This critical work has provided women and healthcare providers with evidence-based management options while contributing to our understanding of the pathogenesis of hereditary cancer.
Additional interests are aimed at identifying prognostic factors for ovarian cancer, a highly fatal disease, and furthering our understanding of how variation in treatment may impact outcomes.
She is also actively involved in the teaching and mentoring of students at the University of Toronto across various stages of their academic careers.
Anita Koushik - Université de Montréal
Anita Koushik is a Research Scientist at the Centre de recherche du CHUM and an Associate Professor in the Département de médecine sociale et preventive at the Université de Montréal and. She received a BSc in Pharmacology from the University of Alberta, an MSc in Community Health & Epidemiology from Queen’s University, and a PhD in Epidemiology & Biostatistics from McGill University. She then conducted postdoctoral training in the Department of Nutrition at the Harvard School of Public Health.
Pamela Ohashi- Princess Margaret Cancer Centre
Dr. Ohashi received her Ph.D from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is a Senior Scientist at the Princess Margaret Cancer
Jim Petrik - University of Guelph
Dr. Jim Petrik is a professor in the Department of Biomedical Sciences at the University of Guelph. Jim is also adjunct faculty in the Department of Obstetrics and Gynecology at McMaster University and Experimental Oncology at Western. Jim's research program focuses on developing novel therapeutic approaches for advanced stage ovarian cancer. His research involves mechanisms to normalize dysfunctional tumor vasculature to improve the uptake and efficacy of various therapies. Jim is also interested in targeting
Ben Tsang - Ottawa Hospital Research Institute
Professor Ben Tsang joined the University of Ottawa (uOttawa) in 1980 as the Director, Reproductive Biology Unit and subsequently served as the Associate Chair (Research) of the Department of Obstetrics and Gynecology and the Director of Research of the Ottawa Civic Hospital. He is currently Full Professor of Obstetrics & Gynaecology and Cellular & Molecular Medicine and Senior Scientist in the Chronic Disease Program, Ottawa Hospital Research Institute (OHRI).
Professor Tsang is internationally recognized for his translational research program in cell fate regulation in women’s reproductive health, especially in the area of anovulatory infertility and chemoresistant ovarian cancer. His research program has been supported continuously by national competitive grants from MRC/CIHR during the past 37 years. He has contributed over 215 full-length original publications and 21 reviews/book chapters, and holds 4 patents. The success of Dr. Tsang’s research is reflected in the numerous honours and awards he received, including the CFAS Award of Excellence in Reproductive Medicine, the Ottawa Centre for Research and Innovations Research Award, the Ottawa Regional Cancer Foundation Angel Award for cancer research excellence, the J David Grimes Research Career Achievement Award, and the uOttawa Faculty of Medicine Award of Excellence. He was appointed the World Class University Professor of Biomodulation at Seoul National University.
Dr. Tsang is the Co-editor-in-Chief of the Journal of Ovarian Research and Associate Editor of Molecular Carcinogenesis and Journal of Cancer Prevention. He has served on the Editorial Board of Endocrinology, Biology of Reproduction, Reproduction, Clinical and Experimental Reproductive Medicine and Adaptive Medicine, and on various CIHR grant committees. He holds honorary professorships at the Chinese Academy of Sciences, Jinan University, Nanjing Medical University and Taipei Medical University.
Professor Tsang served as co-chairs of the China-Canada Bilateral Program on Reproductive Health and the Canada-Japan Bilateral Program on Women’s Health Research in the promotion of international research partnerships and academic exchanges. He served as President of the Canadian Fertility and Andrology Society and a member of the Board of Directors of the Society for the Study of Reproduction (SSR). He is the Chair of the SSR Golden Anniversary Fundraising Campaign.